{
    "clinical_study": {
        "@rank": "20145", 
        "arm_group": [
            {
                "arm_group_label": "Diclofenac", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects assigned to receive 1 tablet of Diclofenac Sodium (50 mg) and two tablets of an indistinguishable placebo three times daily for a duration of 12 weeks."
            }, 
            {
                "arm_group_label": "Wobenzym", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects assigned to receive 2 tablets of Wobenzym(R) and 1 tablet of an indistinguishable placebo three times daily for a duration of 12 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects assigned to receive three tablets of an indistinguishable placebo three times daily for a duration of 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this randomized, double-blind, placebo-controlled, comparator-controlled trial\n      was to evaluate the safety and efficacy of an enzyme combination, as Wobenzym\u00ae, in adults\n      with moderate-to-severe osteoarthritis (OA) of the knee."
        }, 
        "brief_title": "The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults", 
        "completion_date": {
            "#text": "November 2001", 
            "@type": "Actual"
        }, 
        "condition": [
            "Wobenzym", 
            "Osteoarthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Knee osteoarthritis confirmed by radiography or tomography\n\n          -  Lequesne Functional Index score of 10-14\n\n          -  WOMAC-A pain subscale score greater than or equal to 25\n\n        Exclusion Criteria:\n\n          -  History of knee trauma\n\n          -  History of joint infection\n\n          -  History of joint surgery\n\n          -  History of intra-articular injection (viscotherapy)\n\n          -  History of gastrointestinal diseases\n\n          -  Use of corticosteroids\n\n          -  Use of COX-II inhibitors\n\n          -  Use of glucosamine/chondroitin\n\n          -  Known sensitivity to paracetamol\n\n          -  Known sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs)\n\n          -  Known sensitivity to oral enzymes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088411", 
            "org_study_id": "MU-699412"
        }, 
        "intervention": [
            {
                "arm_group_label": "Diclofenac", 
                "intervention_name": "Diclofenac", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Wobenzym", 
                "intervention_name": "Wobenzym", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Diclofenac", 
                "Wobenzym"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oberhaching", 
                    "country": "Germany"
                }, 
                "name": "Mucos Pharma GmbH & Co"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults: a Randomized, Double-blind, Placebo-controlled Trial.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2001", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Self-assessment of the affected knee joint by physician interview using the Lequesne Functional Index (providing an estimate of the degree of pain associated with the affected joint, the maximum distance talked, and activities of daily living).", 
            "measure": "Lequesne Functional Index", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088411"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Western Ontario and McMaster Universities Index version 3.0 subscale for pain (WOMAC-A)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to 12 weeks"
            }, 
            {
                "measure": "Western Ontario and McMaster Universities Index version 3.0 subscale for joint stiffness (WOMAC-B)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to 12 weeks"
            }, 
            {
                "measure": "Western Ontario and McMaster Universities Index version 3.0 subscale for joint function (WOMAC-C)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to 12 weeks"
            }, 
            {
                "description": "Number of paracetamol tablets consumed during the study by subjects", 
                "measure": "Paracetamol Consumption", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to 12 weeks"
            }, 
            {
                "description": "Erythrocyte sedimentation rates at 1 and 2 hours and serum concentration of C-reactive protein", 
                "measure": "Indices of systemic inflammation", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to 12 weeks"
            }, 
            {
                "description": "Any complications throughout study.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Through baseline to 12 weeks"
            }
        ], 
        "source": "Atrium Innovations", 
        "sponsors": {
            "collaborator": {
                "agency": "Mucos Pharma GmbH, Oberhaching, Germany", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Atrium Innovations", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}